Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lifearc
Headquarters: London, United Kingdom
Website: http://www.lifearc.org
Year Founded: 1992
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 19, 2024
Management Tracks
Doug Williams leaving Sana
Plus: Baptista joins SmartCella and updates from LifeArc and Gain
BioCentury | Oct 2, 2023
Management Tracks
GSK vet Lepore named CEO of Flagship’s ProFound
Plus: CEO Simonian retiring as Syros reorganizes, and updates from Broken String, Repligen, AmbioPharm, BPGbio and LifeArc
BioCentury | Feb 15, 2023
Deals
Feb. 15 Quick Takes: Emergent deal to grow Bavarian Nordic footprint in U.S., Europe
Plus: Maxion raises series A to develop mAbs against ion channels, GPCRs and updates from Arrowhead, Moderna, Galera, Codagenix, Nanite
BioCentury | Oct 21, 2022
Politics, Policy & Law
Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool
Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
BioCentury | Sep 8, 2022
Product Development
Sept. 8 Quick Takes: Detailed APOLLO-B data lift Alnylam shares
Plus Autobahn heads for treatment-resistant depression with $32M round and updates on Amylyx, Reata, Integral Molecular and more
BioCentury | Feb 2, 2022
Management Tracks
Roche’s William Pao joins Pfizer as CDO
Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
BioCentury | May 24, 2021
Finance
May 24 Quick Takes: Neurology play Eliem raises $60M series B; plus Xeris-Strongbridge, CARsgen, Janssen, Abivax and Takeda
Two months after emerging from stealth with $80 million, Eliem Therapeutics Inc. closed a $60 million series B round led by Intermediate Capital Group and RA Capital Management to advance a pipeline
BioCentury | May 5, 2021
Deals
May 4 Quick Takes: Oxford Nanopore raises £195M ahead of planned IPO; plus Pfizer, Oculis, MoonLake, Aceragen, Yarrow-ProQR, BioLineRx and more
BioCentury | Feb 9, 2021
Finance
Illumina unveils latest entrants to accelerator in SF, U.K.
Genomics player Illumina has added nine more start-ups to the stable of genomics newcos residing at its Illumina Accelerator. On Monday, Illumina Inc. (NASDAQ:ILMN) announced the latest round of
BioCentury | Oct 31, 2020
Product Development
U.K. BIA Antibody Taskforce picks COVID-19 mAb cocktail candidates
The U.K. BIA Antibody Taskforce is gearing up to start human testing of its cocktails of antiviral COVID-19 mAbs as FDA’s decisions on EUAs are pending for Regeneron’s mAb cocktail and a
Items per page:
1 - 10 of 30